학술논문
Concurrent inhibition of oncogenic and wild-type RAS-GTP for cancer therapy
Document Type
Article
Author
Holderfield, Matthew; Lee, Bianca J.; Jiang, Jingjing; Tomlinson, Aidan; Seamon, Kyle J.; Mira, Alessia; Patrucco, Enrico; Goodhart, Grace; Dilly, Julien; Gindin, Yevgeniy; Dinglasan, Nuntana; Wang, Yingyun; Lai, Lick Pui; Cai, Shurui; Jiang, Lingyan; Nasholm, Nicole; Shifrin, Nataliya; Blaj, Cristina; Shah, Harshit; Evans, James W.; Montazer, Nilufar; Lai, Oliver; Shi, Jade; Ahler, Ethan; Quintana, Elsa; Chang, Stephanie; Salvador, Anthony; Marquez, Abby; Cregg, Jim; Liu, Yang; Milin, Anthony; Chen, Anqi; Ziv, Tamar Bar; Parsons, Dylan; Knox, John E.; Klomp, Jennifer E.; Roth, Jennifer; Rees, Matthew; Ronan, Melissa; Cuevas-Navarro, Antonio; Hu, Feng; Lito, Piro; Santamaria, David; Aguirre, Andrew J.; Waters, Andrew M.; Der, Channing J.; Ambrogio, Chiara; Wang, Zhengping; Gill, Adrian L.; Koltun, Elena S.; Smith, Jacqueline A. M.; Wildes, David; Singh, Mallika
Source
Nature; 20240101, Issue: Preprints p1-8, 8p
Subject
Language
ISSN
00280836; 14764687
Abstract
RAS oncogenes (collectively NRAS, HRASand especially KRAS) are among the most frequently mutated genes in cancer, with common driver mutations occurring at codons 12, 13 and 611. Small molecule inhibitors of the KRAS(G12C) oncoprotein have demonstrated clinical efficacy in patients with multiple cancer types and have led to regulatory approvals for the treatment of non-small cell lung cancer2,3. Nevertheless, KRASG12Cmutations account for only around 15% of KRAS-mutated cancers4,5, and there are no approved KRAS inhibitors for the majority of patients with tumours containing other common KRASmutations. Here we describe RMC-7977, a reversible, tri-complex RAS inhibitor with broad-spectrum activity for the active state of both mutant and wild-type KRAS, NRAS and HRAS variants (a RAS(ON) multi-selective inhibitor). Preclinically, RMC-7977 demonstrated potent activity against RAS-addicted tumours carrying various RAS genotypes, particularly against cancer models with KRAScodon 12 mutations (KRASG12X). Treatment with RMC-7977 led to tumour regression and was well tolerated in diverse RAS-addicted preclinical cancer models. Additionally, RMC-7977 inhibited the growth of KRASG12Ccancer models that are resistant to KRAS(G12C) inhibitors owing to restoration of RAS pathway signalling. Thus, RAS(ON) multi-selective inhibitors can target multiple oncogenic and wild-type RAS isoforms and have the potential to treat a wide range of RAS-addicted cancers with high unmet clinical need. A related RAS(ON) multi-selective inhibitor, RMC-6236, is currently under clinical evaluation in patients with KRAS-mutant solid tumours (ClinicalTrials.gov identifier: NCT05379985).